Global Insulin Pump Market by Type (Patch Pump and Tethered Pump), By Accessories (Insulin Set Insertion Devices and Insulin Reservoir), By End User, By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, and Forecast 2023-2032

Report Overview

In 2022, the global Insulin Pump Market was valued at US$ 4.86 billion. Between 2023 and 2032, this market is estimated to register the highest CAGR of 12.8%. It is estimated to reach a valuation of US$ 15.5 billion by 2032.

Diabetes patients can receive their prescribed amounts of insulin using insulin pumps, which are small, programmed medication delivery systems. The widespread adoption of insulin pumps has been facilitated by their increasing effectiveness in regularly treating and controlling diabetes by delivering consistent and timely insulin doses. The insulin pump market is extremely dependent on the geriatric population.

The rising prevalence of type 1 and type 2 diabetes is the main factor driving the need for insulin pumps. Overweight and obesity lead to an increased occurrence of type II diabetes. That’s why risk factors such as smoking, overweight, obesity, and high cholesterol are expected to increase the prevalence of type II diabetes.

By 2032, it is predicted that 798 million people will have diabetes worldwide, according to information provided by the International Diabetes Federation. The World Health Organization claims that diabetes significantly contributes to kidney failure, blindness, and stroke.

Drivers

The rising diabetic population

The exact cause of diabetes is unknown. However, years of research, studies, and research have produced a list of factors that can significantly increase the risk of diabetes. The major factors are obesity and aging. Nearly 40% of the world’s population is now obese. A sedentary lifestyle and an unhealthy diet are the most common causes of obesity and overweight.

Advances in healthcare have increased life expectancy worldwide. Therefore, the proportion of the elderly population in the total population is increasing. The elderly population is at increased risk of developing diabetes. As a result, the number of diabetics is likely to increase as more and more people become obese or overweight and age.

As awareness of diabetes management and care grows, electronic insulin pumps are preferred by both physicians and consumers. This is because the new generation pumps are convenient, safe, and provide accurate results compared to traditional methods. Anytime, Anywhere The nature of digital technology allows patients to address their health concerns by connecting and sharing data with their healthcare team. The factors mentioned above are expected to drive the growth of the market.

Restraints

Expensive Insulin Pumps

Patients need to take insulin regularly because insulin is necessary to sustain life. These medical devices are the subject of extensive research, development, and innovation requiring huge amounts of capital. After obtaining the necessary approvals, the product is launched, and the company that developed the product must reach break-even and be profitable before the patent expires. In addition, only a few players are in the market, giving you great power over the market price.

A lax regulatory framework and other policy issues allow pharmaceutical companies to set high drug prices without accountability or oversight. Most consumers do not have access to insulin pumps due to their high cost. Subsequent maintenance is expensive, restraining the average person from buying an insulin pump. As a result, the high price of insulin pumps hinders market expansion.

 COVID-19 Impact Analysis

The COVID-19 pandemic has positively impacted the insulin infusion pump market

SARS-CoV-2, the cause of COVID-19, has infected and killed more than millions. Diabetes and unrestricted hyperglycemia are affecting factors in COVID-19 patients and may increase the risk of serious illness and death. People with type 1 diabetes are more affected by COVID-19.

People with diabetes have weak immune systems, and the complications of COVID-19 exacerbate the condition and weaken their immune systems rapidly. People with diabetes are more likely to have serious complications than normal people. Insulin infusion pump manufacturer set to supply insulin delivery devices to diabetics during COVID-19 with help from local government

The sudden onset of the COVID-19 pandemic has increased the use of protective equipment, including insulin pumps, by diabetics to control their blood sugar levels and protect their bodies from the high risk of coronavirus infection.

Type Analysis

Based on type, the market for insulin pumps is segmented into patch pumps and tethered pumps. Among these types in 2022, the patch pumps category dominated the market. Patch pumps are tiny, digital insulin pumps that can be affixed to the skin’s surface. Patch pumps offer increased patient convenience because no tubes are needed to connect the pump and cannula.

Patch pumps can be integrated into or linked to smartphone applications that assist in monitoring blood glucose levels to improve insulin sensitivity. The segment’s expansion will also be aided by using technology to improve features that improve insulin delivery.

Tethered pumps will dominate the market, with patch pumps as a growth leader. When the pump is connected, the plastic cannula and pump are separated by a flexible hose. The reliability of these classic pumps and the abundance of items currently on the market are the two main factors responsible for the significant growth of this market segment.

Accessories Analysis

The accessories market segment is set to be emerging in the insulin pump market. The insulin set insertion devices have a major share in the market, accounting for the largest revenue share in 2022, and is anticipated to continue to rule the market during the projection period.

The market for insulin reservoirs or cartridges is anticipated to increase rapidly over the predicted period. The increasing adoption of tethered pumps drives the growth of the insulin reservoir. This involves loading a new insulin cartridge into the insulin reservoir or extracting insulin into the reservoir.

End-User Analysis

The hospital segment dominated the market and accounted for the largest revenue share in 2022. This is simply due to the increasing penetration of hospitals worldwide daily. Qualified medical professionals who can help people with diabetes effectively cure their diabetes have driven the growth of this segment. Increasing investment in hospital development by governments and companies is expected to further drive the growth of the hospital segment in the near future.

Secondly, the healthcare segment is growing due to the rising healthcare costs, growing awareness of the availability of insulin pumps, and the ease of obtaining insulin pumps through online and offline retail pharmacies have significantly powered the market growth of the home healthcare segment. Additionally, integrating smart technologies, such as artificial intelligence, in the medical field drives patients’ acceptance of automatic insulin pumps.

Key Market Segments

Based on Type

• Patch Pump
• Tethered Pump

Based on Accessories

• Insulin Set Insertion Devices
• Insulin Reservoir

Based on End-User

• Hospitals
• Clinics
• Homecare
• Laboratories

Opportunity

Evolving Insulin Pump Technologies

The increasing prevalence of diabetes has prompted private market participants to invest in better insulin delivery systems to take advantage of the growing diabetes market. Insulin dependence requires regular doses of insulin that are appropriate for the body’s needs. However, given the busy lifestyle patterns of the modern world, tracking blood sugar levels, health awareness, and injecting insulin when needed can be difficult and cumbersome.

Additionally, insulin injections are not the most convenient drug delivery for the elderly. There is a growing demand for integrating artificial intelligence and machine learning in developing computer-assisted insulin pumps that automatically administer insulin as needed after calculating the body’s needs. Product innovations with technological advancements to enhance the insulin delivery system will offer lucrative opportunities for the market.

Trending Factors

The insulin infusion pump market is likely to continue to grow due to rising obesity rates, rising genetic factors for type 2 diabetes, and increasing numbers of people with type 1 diabetes.

Insulin pump manufacturers are increasingly focused on product innovation and differentiation as they steadily move toward consolidation through key factors: mergers & acquisitions, joint ventures, and collaborative partnerships. Such trends are currently being witnessed in this market, bolstering the demand for insulin pumps in the growth of the market.

Regional Analysis

North America Covers Major Market Share than Others.

North America dominates the insulin pump market, with a major revenue share of approximately 47.8% in 2022 due to the presence of major players in insulin pumps. Additionally, rising obesity rates, high treatment costs, technological advancements, and product launches are expected to drive the market in the region.

Europe is also expected to gain a large market share during the forecast period due to the increasing elderly population prone to diabetes. Additionally, improvements in healthcare and the introduction of modern medical products have increased the demand for insulin pumps.

Asia Pacific is expected to be a favorable region for the insulin pump market. Rising healthcare funding and government initiatives to raise awareness of diabetes are key growth drivers in the region. China is expected to lead its APAC region in 2022 due to its economic growth and large diabetic population. Moreover, introducing new technologies in developing countries is expected to boost the market.

Key Regions and Countries Covered in this Report

• North America
  • The US
  • Canada
  • Mexico
• APAC
  • China
  • Japan
  • South Korea
  • India
  • Australia & New Zealand
  • Indonesia
  • Malaysia
  • Philippines
  • Singapore
  • Thailand
  • Vietnam
  • Rest of APAC

• Western Europe
  • Germany
  • France
  • The UK
  • Spain
  • Italy
  • Portugal
  • Ireland
  • Austria
  • Switzerland
  • Benelux
  • Nordic
  • Rest of Western Europe
• Eastern Europe
  • Russia
  • Poland
  • The Czech Republic
  • Greece
  • Rest of Eastern Europe

• Latin America
  • Brazil
  • Colombia
  • Chile
  • Argentina
  • Costa Rica
  • Rest of Latin America
• Middle East & Africa
  • Algeria
  • Egypt
  • Israel
  • Kuwait
  • Nigeria
  • Saudi Arabia
  • South Africa
  • Turkey
  • United Arab Emirates
  • Rest of MEA

Market Share and Key Player Analysis

Medtronic leads the market with a strong position in the insulin pump market:

Key Market players are executing strategies such as mergers and acquisitions, partnerships, and launching new technologically advanced products and services to strengthen their market positions. Major players invest heavily in research and development to produce technologically advanced products. Key companies are adapting and heavily investing in new techniques.

Medtronic has received FDA clearance for the MiniMed 770G insulin product featuring Medtronic’s SmartGuard technology. It can be easily connected to a smartphone and even has modulation for children.

Other prominent players are developing various development strategies such as product launches, acquisitions, partnerships, and mergers that drive market growth and provide lucrative growth opportunities for market participants.

Market Key Players

• Medtronic plc
• F. Hoffmann-La Roche Ltd
• Tandem Diabetic Care Inc.
• Insulet Corporation
• Ypsomed AG
• Cellenovo
• Sooil Development
• Valeritas Inc.
• JingasuDelfu Co. Ltd.
• Cequr SA
• Vicentra B.V.
• Other Key Players

 Recent Developments

• On June 2, 2022, Insulet Corporation, an international chief in tubeless insulin pump gadgets and technology, introduced funding of about USD two hundred million in its upcoming production facility in Johor over the following 5 years. This could produce the company’s Omnipod Insulin Management System as a part of its ambition to bolster its international production skills
• In April 2022, Ypsomed introduced a collaboration with Abbott and CamDiab to expand an incorporated AID (computerized insulin delivery) device. The new incorporated AID device is being designed to hyperlink Abbott’s FreeStyle Libre three with Ypsomed’s MyLife YpsoPump to make a smart and automated manner for handing over insulin with sensible glucose information
• On three June 2022, Diabeloop, an international chief in healing AI, and SOOIL Development Company, a pacesetter in advanced diabetes remedy, introduced a settlement for international improvement on the American Diabetes Association Scientific Sessions. The collaboration is expected to set up scientific trials to increase their cooperation and offer admission to their items to as many sufferers as viable through new revolutionary products.

Report Scope